Aristotle University Of Thessaloniki (AUTH)
Διερεύνηση μοριακών/γενετικών δεικτών για την πρόβλεψη της απάντησης ασθενών με καρκίνο του παχέος εντέρου σε επικουρική χημειοθεραπεία
Abstract
dc:descriptionColorectal cancer (CRC), including cancer of the colon and rectum, develops as a result of multiple molecular/genetic and environmental factors that cumulatively drive oncogenesis, in diverse profiles for each individual. Currently, the assessment of CRC patients is based on the identification in tumor tissues of genetic and phenotypic characteristics with prognostic and/or predictive value. In addition, tumor development and evolution, as well as patient response to the diverse therapeutic modalities in the present armamentarium, depend to a large extent on host anti-tumor immune response. Mapping and understanding the immune contexture of the tumor is ongoing, since it is important for the rational and more efficient use of immunomodulators in the treatment of CRC.The aim of this study was to investigate the prognostic impact of genetic/phenotypic characteristics in tumor tissues from CRC patients with early-stage disease. Patients, tumors and methods: We examined formalin-fixed paraffin-embedded tumor tissues from 414 CRC patients with operable stage II and III disease. Patients were treated in the context of a randomized clinical trial with adjuvant chemotherapy (FOLFOX or XELOX). Except for the standard clinicopathological parameters, we evaluated tumor infiltrating lymphocyte (TILs) density, the presence or absence of necrosis, MMR protein status with immunohistochemistry, as well as the relative mRNA expression of immune response genes (CD3Z, CD8, CD4, CXCL9, CXCL13, IGHM and FOXP3), of the transcription factor SNAI2, and of ESR1, the gene encoding for estrogen receptor type A. We used hierarchical clustering to profile CD3/CD8 expression (mRNA ImmunoScore, mIS) in tumors and, where available, in adjacent normal mucosa.Results: We observed that the absence of necrosis (presence vs. absence HR = 0.44, 95% CI 0.24-0.82, Wald's p = 0.01; HR = 0.40, 95% CI 0.22-0.72, p = 0.002) and the relatively high ESR1 mRNA expression (HR = 2.86, 95% CI 1.60-5.12, p = 0.0004; HR = 1.95, 95% CI 1.10-3.46, p = 0.022) were independent unfavorable parameters conferring higher risk for relapse and death, respectively. In stage III patients with tumor in the right colon, mIS appeared to affect disease-free survival (DFS). In this subgroup, the rate of patients who reached 3-years DFS was 75% if tumor had high mIS compared to 57.1% for tumors with low mIS (HR 3.9, 95%CI 1.05-8.02, p=0.023). By contrast, in stage II patients, low mIS was associated with lower risk for death for tumors located in the right (HR 0.12, 95%CI 0.01–0.94, p=0.041) or in the left (HR 0.12, 95%CI 0.03–0.48, p=0.001) colon. KRAS and BRAF mutations were not associated with MMR protein status or with mIS or with clinicopathological characteristics, while none or these parameters was associated with prognosis. TIL density and mIS in the normal mucosa were also not associated with prognosis. Conclusions: The CD3Z/CD8A immune response profile may diversely affect early CRC prognosis dependent on disease stage and tumor location, which seems worth further investigation in large patient cohorts for obtaining statistical power. ESR1 mRNA expression may be further developed as a prognostic marker and possible therapeutic target in CRC. Lastly, typing necrosis appears as a promising research field for achieving a more rational therapeutic assessment of patients with non-metastatic CRC who have undergone tumor debulking surgeries.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Raptou, Georgia
- Ράπτου, Γεωργία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48838